A clinical trial update dated June 24, 2026 confirms that a Phase 3 study of teduglutide in Chinese adults with short bowel syndrome is currently recruiting participants. The trial, registered as NCT06973304 and titled "A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome," is listed on ClinicalTrials.gov.
Teduglutide is an approved compound, and this study specifically examines its use in a Chinese adult population with short bowel syndrome. The trial is in Phase 3, which typically involves testing in larger patient groups following earlier-phase research.
According to the available record, the study status is recruiting, meaning the trial is actively enrolling participants at this time. No results have been posted for this trial as of the date of this update, and no efficacy or safety outcomes have been disclosed in the available data.
This brief reports only the status and phase information provided in the trial registry entry. Readers interested in the broader context of teduglutide, including its approved uses and regulatory history, can consult the compound overview for additional background.